These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7766149)

  • 1. In vitro and in vivo studies with different precipitate filter cartridges for H.E.L.P.-LDL-apheresis. Optimization of precipitate filter cartridges.
    Morsch G; Maywald F; Wanner C
    Bioseparation; 1995 Feb; 5(1):11-8. PubMed ID: 7766149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [H.E.L.P. apheresis and oxidative stress].
    Pulawski E; Mellwig KP; Horstkotte D
    Z Kardiol; 2003; 92(Suppl 3):III38-41. PubMed ID: 14663600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoprotein apheresis by membrane differential filtration (cascade filtration) via arteriovenous fistula performed in children with familial hypercholesterolemia.
    Gülle S; Bak M; Serdaroglu E; Can D; Karabay O
    Ther Apher Dial; 2010 Feb; 14(1):87-92. PubMed ID: 20438523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Heparin-induced extracorporeal LDL precipitation (H.E.L.P.)].
    Horstkotte D; Mellwig KP
    Z Kardiol; 2003; 92(Suppl 3):III1-5. PubMed ID: 14663596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical long-term results of H.E.L.P.-apheresis].
    Schuff-Werner P
    Z Kardiol; 2003; 92(Suppl 3):III28-9. PubMed ID: 14663598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention of early graft occlusion after coronary bypass grafting by post-operative reduction of plasma fibrinogen by H.E.L.P. apheresis. First evaluation of 12 patients treated during our study (44 bypasses)].
    Blessing F; Jaeger BR; Oberhoffer M; Reichart B; Seidel D
    Z Kardiol; 2003; 92(Suppl 3):III42-7. PubMed ID: 14663601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The H.E.L.P. system: an efficient and safe method for plasma therapy in the treatment of severe hypercholesterolemia.
    Seidel D
    Isr J Med Sci; 1996 Jun; 32(6):407-13. PubMed ID: 8682646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-density lipoprotein apheresis decreases ferritin, transferrin and vitamin B12, which may cause anemia in serially treated patients.
    Bramlage CP; Armstrong VW; Zapf A; Bramlage P; Mueller GA; Koziolek MJ
    Ther Apher Dial; 2010 Apr; 14(2):136-42. PubMed ID: 20438534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulsed flow cascade filtration. Long-term experience in low density lipoprotein and lipoprotein a removal.
    Legallais C; Moriniére P; Fournier A; Jaffrin MY
    ASAIO J; 1996; 42(5):M463-7. PubMed ID: 8944924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [LDL-apheresis in the treatment of coronary heart disease. Rationale for a specific adjuvant therapy].
    Seidel D
    Z Kardiol; 2003; 92(Suppl 3):III6-27. PubMed ID: 14663597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apheresis technologies for prevention and regression of atherosclerosis: clinical results.
    Bambauer R; Schneidewind JM; Latza R
    ASAIO J; 1999; 45(5):403-7. PubMed ID: 10503615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [H.E.L.P. therapy (heparin-induced extracorporeal LDL precipitation) in sudden deafness].
    Walch C; Anderhuber W; Walzl M
    Laryngorhinootologie; 1996 Nov; 75(11):641-5. PubMed ID: 9063830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case report of the cascade filtration system: a safe and effective method for low-density lipoprotein apheresis during pregnancy.
    Ertorer ME; Guvenc B; Haydardedeoglu B; Tekinturhan F
    Ther Apher Dial; 2008 Oct; 12(5):396-400. PubMed ID: 18937724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group.
    Kitabatake A; Sato H; Hori M; Kamada T; Kubori S; Hoki N; Minamino T; Yamada M; Kato T
    Clin Ther; 1994; 16(3):416-28. PubMed ID: 7923308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute effects of LDL-apheresis on cholesterol oxidation products and antioxidants in plasma and lipoproteins of patients with familial hypercholesterolemia.
    Linseisen J; Wilhelm M; Hoffmann J; Hailer S; Keller C; Wolfram G
    Eur J Med Res; 1999 Oct; 4(10):433-41. PubMed ID: 10527957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Extracorporeal plasma therapy in disorders of lipid metabolism: report of experiences with the H.E.L.P. system].
    Seidel D; Thiery J
    Internist (Berl); 1992 Jan; 33(1):54-61. PubMed ID: 1532384
    [No Abstract]   [Full Text] [Related]  

  • 17. Extracorporeal treatment of hypercholesterolaemia.
    Olbricht CJ
    Nephrol Dial Transplant; 1993; 8(9):814-20. PubMed ID: 8255513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic trial of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS).
    Tojo K; Sakai S; Miyahara T
    Prog Clin Biol Res; 1990; 337():193-4. PubMed ID: 2191313
    [No Abstract]   [Full Text] [Related]  

  • 19. Protein adsorption during LDL-apheresis: proteomic analysis.
    Dihazi H; Koziolek MJ; Söllner T; Kahler E; Klingel R; Neuhoff R; Strutz F; Mueller GA
    Nephrol Dial Transplant; 2008 Sep; 23(9):2925-35. PubMed ID: 18398017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Double membrane filtration in LDL-apheresis].
    Yamamoto A; Kojima S
    Nihon Rinsho; 1992 Jan; 50 Suppl():374-81. PubMed ID: 1578710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.